Saturday April 20, 2019

New Combo Therapy Found Effective In Kidney Cancer Patients

With this new combination therapy, tumour shrinkage or stabilization was better than that seen in patients taking just one of the two drugs alone, the researchers found

0
//
The study was published in journal The Lancet Oncology. Wikimedia Commons
The study was published in journal The Lancet Oncology. Wikimedia Commons

Combining an anti-angiogenesis agent, which blocks blood vessel formation, with an immunotherapy agent, has shown promising anti-tumour activity in an early phase clinical trial in patients with advanced kidney cancer who had not been previously treated, says a new study.

The findings of the study involving the combination of anti-angiogenesis agent — axitinib (trade name Inlyta) – and the immunotherapy agent — pembrolizumab (trade name Keytruda) – were published in the journal The Lancet Oncology.

ALSO READ: Battle against Cancer with these foods

“Our results are unprecedented. The combination doubled the efficacy of the drugs when used alone and the treatment was found to be tolerable,” said Michael Atkins of Georgetown University in Washington, DC, and principal investigator for the study.

The immunotherapy agent, pembrolizumab, is an immune checkpoint inhibitor that blocks a self-defense mechanism used by cancer cells to evade attack and destruction by the body's immune cells. Wikimedia Commons
The immunotherapy agent, pembrolizumab, is an immune checkpoint inhibitor that blocks a self-defence mechanism used by cancer cells to evade attack and destruction by the body’s immune cells. Wikimedia Commons

“Specifically, over 90 percent of patients exhibited tumour shrinkage and the disease was kept under control for a median of over 20 months,” Atkins said.

The investigators started their phase-1 clinical trial of this combination in 2014 and enrolled 52 advanced renal cell carcinoma (the most common form of kidney cancer) patients who had not previously been treated for the disease.

ALSO READ: How gut bacteria, broccoli can help keep colorectal cancer away

With this new combination therapy, tumour shrinkage or stabilization was better than that seen in patients taking just one of the two drugs alone, the researchers found.

Patients also had fewer liver abnormalities and less fatigue than those treated with other similar combination therapies, Atkins said.

“We think this combination could present a major advance in the treatment of this disease as well as help define effective combinations of similar drugs for other cancers,” Atkins said. (IANS)

Next Story

This Tiny Cell is Good News for Cancer Survivors

This approach to fertility restoration is safe," says Bhartiya pointing out to earlier studies carried out in her laboratory in mice which had shown that this method restored the role of non-functional ovaries and resulted in the birth of fertile offsprings

0
Cancer
Cancer Ribbon. Pixabay

A scientist at the National Institute for Research in Reproductive Health (NIRRH) in Mumbai — an institute under the Indian Council of Medical Research (ICMR) — says a new type of stem cell identified by her team can help restore fertility in men and women who have undergone treatment for cancer.

Cancer treatment, or “oncotherapy”, that involves use of radiation and chemicals, renders patients infertile as an unwanted side effect and, while cured of cancer, they cannot beget children.

Though women are born with a lifetime reserve of “oocytes” ( immature eggs), these are wiped out by oncotherapy. In males, the testes responsible for the production of sperms, stop making them following cancer treatment.

Currently accepted approaches for fertility preservation require male patients to deposit their sperm in “cryo-banks” before beginning cancer treatment for later use. Similarly women, wanting to have children, must have their eggs or embryos “cryopreserved” for use after oncotherapy.

“Such approaches are invasive, expensive, technically challenging and depend on assisted reproductive technologies,” reports NIRRH cell biologist Deepa Bhartiya in the latest issue of the Indian Journal of Medical Research, the flagship journal of ICMR.

According to the report, there is now a way out. Bhartiya says research by her team over the years led to identification of a novel population of “Very Small Embryonic-Like stem cells (VSELs)”, in testis (in males) and ovaries (in females).

Being “quiescent” by nature, these primitive stem cells (VSELs) survive cancer therapy and therefore can offer young cancer survivors options to have children without having to bank their sperms or embryos prior to oncotherapy, says the report.

“The VSELs have remained elusive over decades due to their small size and presence in very few numbers,” says Bhartiya.

Cancer patient
Cancer patient.

The discovery of these unique VSELs (in testes and ovaries) that do not succumb to oncotherapy “opens up an alternative strategy to regenerate non-functional gonads and ovaries in cancer survivors”, says Bhartiya.

While VSELs survive cancer treatment, their original “habitat” (or niche) however gets destroyed by oncotherapy. To make the VSELs functional, their “niche” should be re-created by transplanting “mesenchymal cells” — another type of stem cells taken from the bone marrow — into the testes, says the report.

A simple and direct transplantation of “mesenchymal cells in the non-functional gonads may suffice to regenerate them,” says Bhartiya. “Similarly, transplantation of “ovarian surface epithelial cells” may allow the VSELs to regenerate nonfunctional ovaries.”

“This approach to fertility restoration is safe,” says Bhartiya pointing out to earlier studies carried out in her laboratory in mice which had shown that this method restored the role of non-functional ovaries and resulted in the birth of fertile offsprings.

“Our group also successfully restored spermatogenesis (sperm production) in non-functional mouse testis by transplanting niche (mesenchymal) cells, into the testis,” Bhartiya said.

Also Read- Micro-blogging Site Twitter to Bring ‘Hide Replies’ Feature in June

In the light of these findings, she says the field of oncofertility may undergo a sea-change and existing strategies of cryopreservation of gametes and gonadal tissue for fertility preservation in cancer patients will have to be revised. “Pilot clinical studies (in humans) need to be undertaken.”

“VSELs may be an alternative cell source for induced Pluripotent Stem (iPS) clls,” Balu Manohar, managing director of Stempeutics Research, a Bengaluru-based stem cell company told this correspondent. “But it is still far away from the clinic as isolation and large scale expansion of these cells has to be standardised.” (IANS)